Gilead Sciences, Inc. (GILD)
NASDAQ • Healthcare
May 22, 2026 at 16:00 UTC
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a biopharmaceutical company focused on antiviral and immunology therapies that are used by health systems around the world. The portfolio spans treatments for infectious diseases and serious chronic conditions, with programs that move from discovery to access through a single, repeatable pathway. Research groups work with clinical partners to translate science into medicines that can be delivered at scale, while medical affairs teams support appropriate use in real settings. Manufacturing and quality systems favor reliability over showy launches, so supply stays steady as demand shifts between regions. The company operates across the Americas, Europe, and Asia with a consistent emphasis on safety, evidence, and responsible distribution. In coverage of large-cap biotech, Gilead Sciences, Inc. stock (GILD) often marks investor interest in therapeutic franchises that combine established use with ongoing research.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Gilead Sciences, Inc.'s Technical Indicators Summary
Gilead’s technicals lean bearish across the short- to medium-term despite the stock remaining above the long-term average. Momentum indicators are negative and short/medium moving averages lie above the current price, signaling near-term weakness, while the 200-day average is below, which keeps longer-term structure less negative. Trend strength is muted and volatility is moderate, and volume metrics offer some support but not enough to offset the mixed signals from price and momentum. Technical takeaway: bearish in the short-to-medium term despite being above the 200-day average.
| Indicator | Value |
|---|---|
RSI (14) | 42.75 |
Stochastic %K (14, 3, 3) | 23.40 |
CCI (20) | -39.44 |
WPR (14) | -74.34 |
Momentum (10) | -5.61 |
MFI | 51.72 |
MACD Level (12, 26) | -1.57 |
Bollinger Bands | $127.27 - $136.16 |
ATR (14) | $3.23 (2.47%) |
ADX (14) | 14.32 |
OBV | 166,776,512 |
Classic Pivot Point | $130.39 |
Fibonacci Pivot Point | $130.39 |
Exponential Moving Averages | $127.26 - $135.19(5 indicators) |
Simple Moving Averages | $128.11 - $137.51(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
By the end of the session, GILD held much of its 2.96% gain versus yesterday, closing around 134.36. The session closed with mild sector strength (1.18%), slightly supporting risk appetite. GILD gains on Tubulis deal strengthening the oncology pipeline and an upbeat Maxim Group buy upgrade, boosting sentiment.
Price Change
from $134.35 close
-$0.02
Trading Volume
Below avg (6.0M)
5.7M
vs S&P 500 Today
Strong Outperformance
+3.55%
52-Week Position
Mid-range
56.6%
Updated: May 22, 2026 at 20:10 UTC
Quote Summary
GILD Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Biotech, Pharma Stocks Draw Fresh Valuation Focus
April 2, 2026
Gilead to buy Ouro, plan Galapagos tie-up
March 23, 2026
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026